Clinical Study
Optimal Erythrocyte Ribavirin Level to Reduce the Risk of Anemia and Obtain an Early Virological Response in Patients with Chronic Hepatitis C Caused by Genotype 1b Infection
Table 2
Comparisons of the rate in which RBV was discontinued, the rate in which RBV dosage was reduced due to development of anemia, 4-week hemoglobin reduction rate from the baseline, the EVR rate and the SVR rate of the patients with 2-week erythrocyte phosphorylated RBV concentration 600 M to 600–800 M, and 800 M .
| ||||||||||||||||||||||||||||||||||||
RBV: ribavirin. Hb: 4-week hemoglobin reduction rate from the baseline. EVR: Early Virological Response; Serum HCV RNA negativity until 12 weeks of therapy. SVR: Sustained Virological Response; Serum HCV RNA negativity at 24 weeks after completed therapy. Hb is expressed as mean S.D. |